Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

	Related Links


	Educational Materials About Clinical Trials Clinical Trials: Questions and Answers Questions to Ask Your Doctor Drug Information from MedlinePlus

Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase IV Treatment Active 18 to 75 Other 2009-04
NCT00874406

Trial Description

Summary

The purpose of this study is to investigate whether preoperative TAC is able to improve progression free survival and overall survival in patients receiving liver metastasis resection of colorectal cancer.

Further Study Information

We administered TAC(oxaliplatin,FUDR and MMC) 7 days before liver metastasis resection of colorectal cancer. The study endpoints were progression free survival and overall survival as evaluated by intent-to-treat analysis.

Eligibility Criteria

Inclusion Criteria:

age <= 75 years

resectable liver metastasis

remnant liver volume >= 70%

without other organ metastasis or peritoneum metastasis

without contradiction of cardiac and pulmonary diseases

Exclusion Criteria:

age > 75 years

unresectable liver metastasis

remnant liver volume < 50%

with other organ metastasis or peritoneum metastasis

with contradiction of cardiac and pulmonary diseases

Trial Contact Information

Trial Lead Organizations/Sponsors

Medical Center of Fudan University

jianmin xu, MD, PHD

Principal Investigator

jianmin xu, MD, PHD		Ph: 008613501984869
		Email: xujmin@yahoo.com.cn

Trial Sites

China

shanghai

Medical Center of Fudan University

jianmin xu, MD, PHD Ph: 008613501984869

Email: xujmin@yahoo.com.cn

jianmin xu, MD, PHD Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00874406
Information obtained from ClinicalTrials.gov on April 02, 2009

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.